Previous 10 | Next 10 |
Immunomedics (NASDAQ: IMMU ) announces positive results from a Phase 3 clinical trial, ASCENT , evaluating antibody-drug conjugate (ADC) Trodelvy (sacituzumab govitecan-hziy) in patients with relapsed/refractory triple-negative breast cancer (TNBC). More news on: Immunomedics, Inc., Hea...
Trodelvy significantly improved progression-free survival (PFS) and overall survival (OS) in previously-treated brain metastasis negative patients with advanced mTNBC The safety profile of Trodelvy was consistent with the FDA-approved label and no new safety signals were observed ...
Immunomedics (NASDAQ: IMMU ) is up 3.4% after hours following notice it's holding a conference call/webcast to offer a clinical update . More news on: Immunomedics, Inc., Healthcare stocks news, Stocks on the move, Read more ...
MORRIS PLAINS, N.J., July 02, 2020 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates, today announced that the Company will host a conferenc...
Bank of America starts off Q3 with a reset of its closely-watched US 1 list. More news on: Hilton Worldwide Holdings Inc., L Brands, Inc., Constellation Brands, Inc., Consumer stocks news, Read more ...
Market Pulse The question of whether it's a new bull market rally or just an intermittent bear market rally doomed to end later this year will most likely be decided late in the third quarter or during the fourth quarter when enough evidence on the durability of the recovery pace is forthcom...
The following slide deck was published by Immunomedics, Inc. in conjunction with this Read more ...
Immunomedics (NASDAQ: IMMU ) announces that President & CEO Harout Semerjian has decided to step down effective immediately due to COVID-19-related "logistical obstacles." More news on: Immunomedics, Inc., Healthcare stocks news, Stocks on the move, Read more ...
MORRIS PLAINS, N.J., May 27, 2020 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates, today provided a business update on a leadership change...
MORRIS PLAINS, N.J., May 13, 2020 (GLOBE NEWSWIRE) -- Immunomedics, Inc. , (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today announced that its recently FDA-approved A...
News, Short Squeeze, Breakout and More Instantly...
Gilead Sciences (NASDAQ: GILD) can be both a hero and a goat, depending on your perspective as an investor. The stock price rose from $17 in July 2010 to $118 in July 2015, as the company introduced revolutionary HIV drugs and helped bring a cure for hepatitis C to market. Since the...
With huge investments being made in biotech thanks to the pandemic, there has been a renewed focus on biotech stocks. Here are three worth considering: Amgen (AMGN), Immunomedics (IMMU), Seattle Genetics (SGEN), and Genmab (GMAB). The biotechnology industry has rightfully received a huge ...
MORRIS PLAINS, N.J., Oct. 12, 2020 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates, today announced that the Office of Orphan Products...